MannKind Corporation

Financials

Flusso di cassa derivante dalle attività operative 22.64 M-6.38 M8.95 M23.64 M-7.96 M 18.25 M Flussi di cassa derivanti dalle attività di investimento 48.22 M5.96 M6.26 M-25.06 M-291.96 M -304.8 M Liquidità derivante dalle attività di finanziamento -86.9 M1.39 M-5.51 M71.81 M247.41 M 315.1 M Liquidità libera 19.75 M-6.71 M7.83 M22.52 M-9.95 M 13.69 M

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991. MannKind Corporation was named after its founder, Alfred E. Mann.

MNKD

Financials

MannKind Corporation

Notizie

Leerink conferma Outperform su MannKind, vede una reazione eccessiva

Truist conferma il rating su MannKind dopo i dati di trial del partner

MannKind: Strategic Uncertainty Follows United Therapeutics’ Pivot (NASDAQ:MNKD)

MannKind alla Conferenza Sanitaria Barclays: Crescita Strategica

MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation

MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

MannKind alla Leerink Global Healthcare: Nuovi orizzonti nel pharma

MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma

MannKind presenta dati su Afrezza alla conferenza sul diabete

MannKind presents Afrezza data at diabetes conference

MannKind salda note convertibili da 36,3 mln $ con contanti e azioni

MannKind settles $36.3M convertible notes with cash, shares